ALA Diagnostics is a Spanish biotechnology company specialized in the development of innovative diagnostic solutions in the field of neurological diseases, with an initial focus on Multiple Sclerosis (MS).
Our mission is to accelerate and simplify the diagnosis of complex pathologies through the development of validated biomarkers and in vitro diagnostic (IVD) kits based on ELISA technology, offering rapid, accurate, and clinically validated results.
Headquartered in Madrid, ALA Diagnostics is committed to providing non-invasive, affordable, and clinically valuable tools capable of transforming the diagnostic approach to Multiple Sclerosis and other diseases with unmet medical needs.
Our commitment is to promote a more personalized, accessible, and equitable medicine, bringing biomedical innovation with real impact on patients’ lives and on global medical practice.
ALA Diagnostics has a highly qualified team with extensive experience in biotechnology, diagnostics, and clinical development:
Executive Team:
• José Ramón Montero, CEO and Founder
• Dr. Óscar Fernández, Clinical Director and Founder
• Dr. Susana Frago, Laboratory Director
• Amparo Fornés, Chief Financial Officer
Key Team Members:
• Beatriz Tamés, Project Coordinator
• Gema Escalera, Laboratory Technician
• Sonia Sánchez, Laboratory Technician
The team is supported by a network of strategic advisors in regulatory affairs, industrial property, and international partnerships, with experience in leading IVD companies and multicenter clinical trials.
• Development of diagnostic biomarkers and in vitro diagnostic (IVD) kits.
• Design, validation, and industrial transfer of assays based on ELISA technology.
• Regulatory and quality management in compliance with ISO 13485:2016.
• Technical and scientific consulting in neurological diagnostics.
• Collaboration with hospitals, CROs, and the IVD industry for clinical validation and commercialization.
We specialize in the research, development, and validation of in vitro diagnostic kits, combining expertise in molecular biology, immunology, and clinical diagnostics to transform the diagnostic process for complex diseases and facilitate their integration into routine medical practice.
Main Project
Our first product, the ALA Diagnostics MS Kit, represents a milestone in the diagnosis of Multiple Sclerosis (MS).
It is the first non-invasive, rapid, cost-effective, and reliable system capable of detecting the disease from a simple blood sample. This innovation enables early diagnosis, facilitating faster access to treatment and preventing irreversible neurological damage.
The MS Kit is currently in the international clinical trial phase, with a commercial launch planned for 2026.
To achieve this goal, ALA Diagnostics has launched a crowdfunding campaign aimed at completing the final stage of development and bringing this innovation to hospitals and patients worldwide.
ALA Diagnostics is revolutionizing the diagnosis of Multiple Sclerosis with the MS KIT, the first clinically validated blood test for early diagnosis of the disease.
• Based on proprietary biomarkers and an integrated diagnostic algorithm.
• Provides results within one day with over 90% reliability.
• Automatable, scalable, and universal, with simple manufacturing and compatibility with standard clinical laboratories.
• Validated with more than 800 human samples.
• Commitment to personalized medicine and equitable access to healthcare.
• Consolidated public-private financing and strong institutional support.
• The company is currently initiating its international clinical trial, with market launch planned for 2026.
• Hospitals and clinical laboratories interested in new diagnostic tools.
• IVD companies seeking innovative technologies in the field of neurological diagnostics.
• Healthcare institutions and research centers specialized in autoimmune or neurodegenerative diseases.
• Investors and industrial partners in the scale-up and international commercialization stages.
